Trial Type: Early Phase Trials for Multiple Cancer Types

A Phase 1 Study of NM32-2668 (Anti ROR1/Anti CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors
Contact: Dr. Benedito Carneiro
A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer
Contact: Dr. Cara Mathews
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Contact: Dr. Cara Mathews
A phase II, open -label, multi-center, basket study of the ATR kinase inhibitor ART0380 administered orally as monotherapy to patients with biologically selected advanced or metastatic solid tumors
Contact: Dr. Cara Mathews
LS-P-COASTAL: Phase I study of inhibitor of SIRPa-CD47 axis with trastuzumab and deruxtecan for HER2+ solid tumors and cohort for HER2 low breast cancer
Contact: Dr. Stephanie Graff
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
Contact: Dr. Adam Olszewski
LS-P-SODA: Phase I study of antibody-drug-conjugate (DS-3939) targeting tumors expressing TA-MUC-1
Contact: Dr. Benedito Carneiro
LS-P-Poppy: First-in-class antibody-drug conjugate (ADC) targeting fibronectin (PYX-201) for solid tumors
Contact: Dr. Benedito Carneiro
LS-P-START: A phase I study with a novel IL-2 (DF6215) for solid tumors
Contact: Dr. Benedito Carneiro
LS-P-Lasso: A phase I study of bispecific antibody targeting PD-1 and TGFbR2 for solid tumors (INCA33890)
Contact: Dr. Benedito Carneiro